Case report: Delirium due to a diltiazem-fentanyl CYP3A4 drug interaction

General Hospital Psychiatry

Volumn 32, Issue 6, 2010, Pages 648.e9-648.e10

  Levin, Tomer T ^a   Bakr, Mohamed Hussien ^a   Nikolova, Tanya ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Delirium; Diltiazem; Drug interaction CYP3A4; Fentanyl

Indexed keywords

CYTOCHROME P450 3A4; DILTIAZEM; DOCUSATE SODIUM; FENTANYL; HALOPERIDOL; HYDROMORPHONE; LANSOPRAZOLE; LORAZEPAM; OXYCODONE; PIPERACILLIN PLUS TAZOBACTAM; RANITIDINE; TAMSULOSIN; VANCOMYCIN;

AGED; AGGRESSION; AGITATION; ANAMNESIS; ARTICLE; BACKACHE; BEDTIME DOSAGE; CASE REPORT; CHRONIC PAIN; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; CONFUSION; DELIRIUM; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG POTENTIATION; DRUG WITHDRAWAL; HALLUCINATION; HUMAN; HUMAN CELL; LABORATORY TEST; LOW DRUG DOSE; MALE; PERSECUTORY DELUSION; RESPIRATION DEPRESSION; SIDE EFFECT; SOMNOLENCE; SUPRAVENTRICULAR TACHYCARDIA; THORAX PAIN;

EID: 78649503393     PISSN: 01638343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2010.08.003     Document Type: Article

References (7)

1. Armstrong S., Cozza K. Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, Part I. Psychosomatics 2003, 44:167-171.
2. Janssen Pharmaceutica, Duragesic (fentanyl transdermal system) prescribing information 2008, Titusville, New Jersey.
3. Ahonen J., Olkkola K.T., Salmenper M., Hynynen M., Neuvonen P.J. Effect of diltiazem on midazolam and alfentanil disposition in patients undergoing coronary artery bypass grafting. Anesthesiology 1996, 85:1246-1252.
4. Zhou S.F. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 2008, 9:310-322.
5. Zhou S., Chan E., Lim L., Boelsterli U., Li S., Wang J., et al. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr Drug Metab 2004, 5:415-442.
6. Zhou S.F., Liu J.P., Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 2009, 41:89-295.
7. Ingelman-Sundberg M., Sim S., Gomez A., Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007, 116:496-526.